STAA
A quarter that finally has some sparkle
STAAR Surgical reported first-quarter 2026 results, and the company’s top line came in looking a lot less squinty than it has lately. Net sales hit $93.5 million, up 119.6% from a year ago, while gross margin widened to 73.6% from 65.8%. Net income landed at $5.2 million, or $0.10 per diluted share.
The real story: China is doing the heavy lifting
If you strip out China, sales were $46.1 million, up just 6% year over year. That’s the part investors should keep one eye on, because it suggests the big headline growth is being powered by a very specific market rather than a full-blown everywhere-is-on-fire demand boom.
- Total sales: $93.5 million
- Sales excluding China: $46.1 million
- Gross margin: 73.6%
- Net income: $5.2 million, or $0.10 per share
Why the market should care
For a med-tech name like STAAR, the question isn’t just “did sales rise?” It’s “is this a durable recovery or a one-country victory lap?” China has been the swing factor here, so any investor reaction will probably hinge on whether this quarter looks like a turnaround or just a very dramatic cameo.
Big picture: STAAR gave investors a prettier scoreboard, but the sustainability question is still hanging around like the last guest at a party who won’t take the hint.